UroGen Pharma
URGN
URGN
60 hedge funds and large institutions have $482M invested in UroGen Pharma in 2018 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
60
Holders Change
+17
Holders Change %
+39.53%
% of All Funds
1.38%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
23
Increased
21
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$22.6M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$17M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11.9M |
| 4 |
BlackRock
New York
|
+$4.47M |
| 5 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$3.65M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$20M |
| 2 |
PAI
ProQuest Associates IV
Naples,
Florida
|
-$15.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.85M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.87M |
| 5 |
DP
DSAM Partners
London,
United Kingdom
|
-$3.32M |
